Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

QUANTERIX CORPORATION

(QTRX)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
11.75 USD   -0.34%
11/17Quanterix to Participate in the 15th Clinical Trials on Alzheimer's Disease Task Force
AQ
11/16Quanterix to Participate in the 15th Clinical Trials on Alzheimer's Disease (CTAD) Task Force
BU
11/10Quanterix to Participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
BU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/18/2022 11/21/2022 11/22/2022 11/23/2022 11/25/2022 Date
11.73(c) 11.91(c) 12.04(c) 11.79(c) 11.75(c) Last
447 764 327 050 745 252 216 815 69 380 Volume
+4.92% +1.53% +1.09% -2.08% -0.34% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 105 M - -
Net income 2022 -97,6 M - -
Net cash position 2022 320 M - -
P/E ratio 2022 -4,50x
Yield 2022 -
Sales 2023 110 M - -
Net income 2023 -80,0 M - -
Net cash position 2023 263 M - -
P/E ratio 2023 -6,05x
Yield 2023 -
Capitalization 435 M 435 M -
EV / Sales 2022 1,10x
EV / Sales 2023 1,57x
Nbr of Employees 460
Free-Float 92,2%
More Financials
Company
Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum and other... 
Sector
Advanced Medical Equipment & Technology
Calendar
11/29 | 12:55pmPresentation
More about the company
Ratings of Quanterix Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about QUANTERIX CORPORATION
11/17Quanterix to Participate in the 15th Clinical Trials on Alzheimer's Disease Task Force
AQ
11/16Quanterix to Participate in the 15th Clinical Trials on Alzheimer's Disease (CTAD) Task..
BU
11/10Quanterix to Participate in the Canaccord MedTech, Diagnostics and Digital Health & Ser..
BU
11/10Goldman Sachs Adjusts Price Target on Quanterix to $13 From $15, Maintains Neutral Rati..
MT
11/09QUANTERIX CORP Management's Discussion and Analysis of Financial Condition and Results..
AQ
11/08Quanterix Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year of..
CI
11/08Transcript : Quanterix Corporation, Q3 2022 Earnings Call, Nov 08, 2022
CI
11/08Quanterix Corporation Reports Goodwill Impairment for the Third Quarter Ended September..
CI
11/08Earnings Flash (QTRX) QUANTERIX CORPORATION Reports Q3 Revenue $26.6M, vs. Street Est o..
MT
11/08Quanterix Corporation Releases Operating Results for Third Quarter 2022
BU
11/08Quanterix Corporation Reports Earnings Results for the Third Quarter and Nine Months En..
CI
11/01Quanterix' Third Quarter 2022 Earnings Conference Call
BU
10/14Quanterix : Q3 2022 Earnings Call
PU
09/09Quanterix Promotes Daniel Pikora to Chief Operating Officer
MT
09/08Quanterix Corp : Change in Directors or Principal Officers, Financial Statements and Exhib..
AQ
More news
News in other languages on QUANTERIX CORPORATION
11/08Quanterix Corporation fournit des prévisions de revenus pour le quatrième trimestre et ..
11/08Quanterix Corporation annonce ses résultats pour le troisième trimestre et les neuf moi..
09/08Quanterix Corporation nomme Daniel Pikora au poste de directeur de l'exploitation
08/16Achat d'initiés : Quanterix
08/16Achat d'initiés : Quanterix
More news
Analyst Recommendations on QUANTERIX CORPORATION
More recommendations
ETFs positioned on QUANTERIX CORPORATIONETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
BMO MSCI Genomic Innovation Index ETF - CAD0.05%0.24%-NC
IShares Biotechnology ETF - USD0.03%0.06%-NC
IShares Russell 2000 Value ETF - USD0.03%1.18%United_States
Vanguard Russell 2000 Value ETF - USD0.03%1.20%United_States
IShares Russell 2000 ETF - USD0.02%0.51%United_States
More ETFs positioned on QUANTERIX CORPORATION
Chart QUANTERIX CORPORATION
Duration : Period :
Quanterix Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QUANTERIX CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 11,75 $
Average target price 13,75 $
Spread / Average Target 17,0%
EPS Revisions
Managers and Directors
Masoud Toloue President, Chief Executive Officer & Director
Michael A. Doyle Chief Financial Officer
Martin D. Madaus Chairman
David C. Duffy Chief Technology Officer & Vice President-Research
Richard Haigh Senior Vice President-Research Products
Sector and Competitors
1st jan.Capi. (M$)
QUANTERIX CORPORATION-72.29%435
THERMO FISHER SCIENTIFIC-17.38%217 219
DANAHER CORPORATION-18.84%194 395
INTUITIVE SURGICAL, INC.-26.40%93 693
BOSTON SCIENTIFIC CORPORATION3.32%63 237
SIEMENS HEALTHINEERS AG-21.67%59 953